Vienna-based biotech company Marinomed obtains EU-wide certification for new cold medication

(firmenpresse) -


Vienna, 7 August 2018. Vienna-based company Marinomed Biotech AG (Marinomed) today announced it had secured EU-wide certification for a new product: a nasal spray that allows the decongestion of the nasal cavity without employing a pharmaceutical ingredient and tackles viral infections of the airways at the same time. The groundbreaking combination is based on a formulation for which Marinomed has submitted a patent application. This would allow the company to use its patented agent Carragelose

As a result, Marinomed is set to further expand its product range, which currently comprises of five different products including nasal, throat sprays and lozenges, available in over 30 countries.

All Marinomed products launched to date are effective against cold viruses. Their efficacy is based on Carragelose

A new formulation has been developed in Marinomed
 
About Marinomed Biotech AG
Marinomed is a Vienna based biopharmaceutical company focusing on the development of innovative products in the field of respiratory and ophthalmological diseases based on its IP protected technology platforms.
The platform Carragelose
Marinosolv
Further information is available at www.marinomed.com and www.carragelose.com.

Contact
Dr Eva Prieschl-Grassauer
Chief Scientific Officer
Veterin
1210 Vienna, Austria
Tel. +43 (0)1 25077 4460
E-mail: eva.prieschl(at)marinomed.com
http://www.marinomed.com

Contact for media requests:
PR&D & Education
Mariannengasse 8
1090 Vienna, Austria
Tel. +43 (0)1 5057044
E-mail: contact(at)prd.at
http://www.prd.at

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Leseranfragen:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: PRD
Datum: 07.08.2018 - 03:17 Uhr
Sprache: Deutsch
News-ID 1539474
Anzahl Zeichen: 3515

contact information:
Contact person: TCJ
Town:

Wien

Phone: 01 505 70 44

Kategorie:

Pharmaceuticals & Biotech

Typ of Press Release: Erfolgsprojekt
type of sending: Veröffentlichung
Date of sending: 07.08.2018
Anmerkungen:


Diese Pressemitteilung wurde bisher 315 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Vienna-based biotech company Marinomed obtains EU-wide certification for new cold medication
"
steht unter der journalistisch-redaktionellen Verantwortung von

PR&D (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

"BREAK EVEN": New laboratory creates excellent conditions for studying ...

Karl Landsteiner Private University in Krems opens new biomechanics laboratory Krems, 21 March 2018 − A brand new biomechanics laboratory equipped with latest technology is coming on stream at Karl Landsteiner Private University of Heal ...

Bioremediation Fungus Yields its Secrets ...

Vienna, 29. November 2017 – Thanks to genes acquired from bacteria, a fungus can degrade an environmentally harmful hydrocarbon - and comes under considerable stress in the process. These remarkable research findings, which were published recently, ...

New hope for butterfly children ...

The Greek term lysis means "dissolution" and is familiar from words such as "electrolysis". In the case of the genetic disease epidermolysis bullosa it refers to severe skin damage. Sufferers are called "butterfly children&qu ...

Alle Meldungen von PR&D